Enhancement of bioreductive drug toxicity in murine tumours by inhibition of the activity of nitric oxide synthase
1997

Enhancing Cancer Drug Effectiveness with Nitric Oxide Inhibition

Sample size: 6 publication Evidence: moderate

Author Information

Author(s): SA Butler, PJ Wood, S Cole, C Williams, GE Adams, IJ Stratford

Primary Institution: Medical Research Council, Harwell, Oxon OX11 ORD, UK

Hypothesis

Inhibition of nitric oxide synthase activity may enhance the effectiveness of bioreductive drugs in treating tumors by increasing hypoxia.

Conclusion

Combining the nitric oxide synthase inhibitor nitro-L-arginine with the bioreductive drug RB6145 significantly increases anti-tumor activity in murine tumors.

Supporting Evidence

  • Combining nitro-L-arginine with RB6145 reduced survival of KHT tumor cells by 3-4 logs.
  • RB6145 or nitro-L-arginine alone caused no more than 20% cell kill.
  • The tumor response to the drug combination was dependent on tumor size.
  • Histological examination showed increased necrosis in tumors treated with the drug combination.

Takeaway

This study found that a special drug can work better against tumors when another drug is used to block a certain chemical in the body, making the tumors less healthy.

Methodology

Mice with tumors were treated with RB6145 and nitro-L-arginine, and tumor cell survival was assessed using clonogenic assays.

Limitations

The study was conducted in murine models, which may not fully represent human responses.

Participant Demographics

Male and female C3H/He mice, aged 8-12 weeks.

Statistical Information

P-Value

p<0.05

Statistical Significance

p<0.05

Want to read the original?

Access the complete publication on the publisher's website

View Original Publication